Ipca Laboratories reports 37% rise in Q3 net profit

30 Jan 2013 Evaluate

Ipca Laboratories has reported results for third quarter ended December 31, 2012.

The company has reported 37.48% rise in its net profit at Rs 87.89 crore for the quarter as compared to Rs 63.93 crore for the same quarter in the previous year. Total income of the company has increased by 13.92% at Rs 704.99 crore for quarter under review as compared to Rs 618.86 crore for the quarter ended December 31, 2011.

Pursuant to the scheme of amalgamation of Tonira Pharma (Tonira) with the company w.e.f. appointed date April 01, 2011, the results of operations for the quarter and nine months ended December, 2012 includes the operations of the business of Tonira. Since this effect of amalgamation was given in the quarter ended March,2012, the figures of the comparative quarter and nine months ended December,2011 does not include the result of operations of Tonira and hence not comparable.

IPCA Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.

Ipca Laboratories Share Price

1459.30 2.15 (0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×